by Paul Lelieveld | Apr 21, 2021 | Meneldor News
• German Federal Ministry of Education and Research (BMBF) awards Atriva up to €11.4 million for the clinical development of a drug to treat COVID-19 • Product candidate ATR-002 could help hospital patients with COVID-19 avoid ventilation and intensive care treatment...
by Paul Lelieveld | Apr 13, 2021 | Meneldor News
Olaf Althaus appointed Chief Financial Officer Stephan Stenglein, M.D., recently joined as Chief Medical Officer Proven track record and 20+ years of experience in their respective fields of expertise Tübingen (Germany), April 13, 2021 – Atriva Therapeutics GmbH, a...
by Paul Lelieveld | Apr 13, 2021 | Meneldor News
• Charité – Universitätsmedizin Berlin, Germany, enrolls first patient in Phase II study to assess oral treatment ATR-002 • RESPIRE is a placebo-controlled, international, multi-center trial in hospitalized patients with moderate to severe COVID-19 Tübingen (Germany),...
by Paul Lelieveld | Mar 18, 2021 | Meneldor News
NEW YORK — UK-based reagent provider Aptamer Group said on Thursday that it has partnered with Mologic to develop a rapid aptamer-based SARS-CoV-2 antigen test. Aptamer is developing a rapid lateral flow assay, called AptaDx, that is designed to rapidly detect the...
by Paul Lelieveld | Mar 1, 2021 | Meneldor News
A post cast about LightOx and its CEO Sam Whitehouse: https://www.harlandsaccountants.co.uk/podcasts/developing-new-therapeutic-solutions-to-improve-patients-function-and-long-term-outcomes-with-oral-cancer
